EPZICOM Drug Patent Profile

Which patents cover Epzicom, and what generic alternatives are available?

Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epzicom

A generic version of EPZICOM was approved as abacavir sulfate; lamivudine by CHARTWELL RX on March 28^th, 2017.

Summary for EPZICOM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	21
Drug Prices:	Drug price information for EPZICOM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPZICOM
What excipients (inactive ingredients) are in EPZICOM?	EPZICOM excipients list
DailyMed Link:	EPZICOM at DailyMed

See drug prices for EPZICOM

Recent Clinical Trials for EPZICOM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme Corp.	Phase 3
AIDS Clinical Trials Group	Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3

See all EPZICOM clinical trials

Paragraph IV (Patent) Challenges for EPZICOM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPZICOM	Tablets	abacavir sulfate; lamivudine	600 mg/300 mg	021652	1	2007-09-27

US Patents and Regulatory Information for EPZICOM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004		DISCN	Yes	No

Expired US Patents for EPZICOM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	6,180,639

International Patents for EPZICOM

When does loss-of-exclusivity occur for EPZICOM?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPZICOM around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	101	Therapeutic Nucleosides
African Regional IP Organization (ARIPO)	196	Therapeutic nucleosides
African Regional IP Organization (ARIPO)	8900129
African Regional IP Organization (ARIPO)	9000234

Supplementary Protection Certificates for EPZICOM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0382526	SPC/GB96/043	United Kingdom		PRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
0382526	96C0035	Belgium		PRODUCT NAME: LAMIVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/015/001 19960808; FIRST REGISTRATION: CH 53 662 013 19960228
0382526	C960025	Netherlands		PRODUCT NAME: LAMIVUDINUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/015/001 - EU/1/96/015/002 19960808
0817637	91171	Luxembourg		91171, EXPIRES: 20191217

Last updated: July 13, 2026

Epzicom Market Dynamics and Financial Trajectory (Ziagen/Trizivir-Style Competitive Set, Global HIV Market Shift, and Generic/Biosimilar Risk)

Executive summary: Epzicom (abacavir sulfate + lamivudine) has moved from “growth-era” antiretroviral uptake to a mature, price-compressed segment driven by (1) sustained generic penetration, (2) regimen simplification toward once-daily fixed-dose combinations and higher genetic barrier options, and (3) steady policy and guideline shifts away from older nucleoside backbones in new starts. Financial trajectory is characterized by declining originator revenue in major markets, with continued low-to-mid single product revenue survival where branded supply remains, offset by generic volume and channel contracting. Patent and exclusivity have largely cleared for generic entry long ago, leaving commercial dynamics dominated by wholesale pricing, payer formularies, and substitution rules rather than patent exclusivity.

---

Why did Epzicom’s market shrink after early HIV uptake?

Answer: Epzicom’s branded market contracted as generic abacavir/lamivudine combinations entered, and HIV treatment standards moved toward simpler, once-daily regimens and newer antiretroviral classes for new patients.

What regimen trends drove displacement of Epzicom?

• Shift in first-line HIV therapy toward once-daily fixed-dose combinations.
• Increased use of integrase inhibitor–based regimens as the backbone in major guidelines.
• Ongoing preference for single-tablet regimens to improve adherence and reduce regimen complexity.

Where does Epzicom still fit in clinical practice?

• Continuation therapy in patients stabilized on abacavir/lamivudine.
• Settings where a clinician needs two nucleoside components that can be delivered as a fixed dose with a particular third agent strategy.
• Supply continuity in health systems that historically used the combination.

---

What are the key market dynamics affecting Epzicom sales today?

Answer: Pricing pressure, generic substitution, payer formulary design, and inventory/channel behavior are now the main drivers.

1) Generic substitution and wholesale pricing

• Once branded abacavir/lamivudine fixed-dose combinations faced generic competition, the market moved to price-per-tablet benchmarking against generic equivalents.
• Contracting in large tenders and hospital formularies typically selects the lowest-cost therapeutically equivalent product.

2) Payer and formulary behavior

• Epzicom tends to be treated as a “therapeutic alternative” within NRTI backbone choices rather than a preferred product.
• Budget impact decisions usually favor generics unless a payer has a supply or procurement lock-in.

3) Channel inventory and tender cycles

• HIV drug procurement often operates on multi-quarter contracts; branded inventory levels can fall quickly once a system adds a generic.
• When procurement cycles reset, price discounting can widen further.

---

How does Epzicom compare with Trizivir and other abacavir/lamivudine competitors?

Answer: Epzicom competes primarily against generic abacavir + lamivudine combinations and adjacent fixed-dose formats that can be more convenient or bundled with additional agents.

Competitive set snapshot

Product	Components	Convenience level	Typical competitive role
Epzicom	abacavir + lamivudine	2-in-1 (no third drug)	NRTI backbone component
Trizivir	abacavir + lamivudine + zidovudine	3-in-1	older multi-NRTI approach; less favored in modern guidelines
Generic abacavir/lamivudine	same actives as Epzicom	varies by formulation	dominant on price
Other NRTI backbones	e.g., TDF/FTC, TAF/FTC (class dependent)	often 2-in-1 or 1-tablet strategies	guideline-driven displacement

What makes Epzicom’s competitive position weaker now?

• It is not a stand-alone regimen; clinicians still need the third agent.
• Modern standards often prioritize integrase inhibitor backbones and simplified once-daily structures, increasing cross-backbone substitution.

---

When does Epzicom lose exclusivity, and when did generics become dominant?

Answer: Epzicom exclusivity cleared years ago in most major markets, and generic abacavir/lamivudine fixed-dose combinations became the default commercial option.

Exclusivity vs patent reality

• In mature HIV antiretroviral markets, branded NRTI combinations typically face:
  • early patent expiry
  • follow-on formulation and method patents that often do not block generic entry for long
  • Paragraph IV filings in some cases historically for antiretroviral products
• For Epzicom, generic penetration is the dominant commercial outcome rather than ongoing exclusivity-based protection.

---

What is the Orange Book status of Epzicom (and what does it mean for generic entry)?

Answer: Orange Book status is primarily a listing and patent-expiration map used to support generic certification; Epzicom’s branded commercial viability is already dominated by generic substitution.

Why Orange Book status matters commercially

• When relevant patents expire or are carved out, FDA approval pathways allow generics to launch without ongoing legal barriers.
• In a mature segment, even if some patents remain, competitive market forces often push formularies to switch.

---

What patent estate protects Epzicom formulations and methods?

Answer: For antiretroviral fixed-dose combinations like Epzicom, remaining patent coverage typically clusters around:

• formulation details (tablet composition, excipients, manufacturing process)
• specific dosing regimens or method-of-use claims

How strong is the protection typically in this category?

• In practice, once active ingredients have broad prior-art histories and older patents expire, the remaining estate often becomes narrower.
• Narrow estate protection usually reduces the time window for exclusivity blocking and shifts litigation risk from preventing launch to managing switching and sales mitigation.

---

What generic entry risks exist for Epzicom?

Answer: The risk profile is mostly “already realized.” Market access risk is less about whether generics can launch and more about the impact on branded pricing and distribution.

Post-launch dynamics

• New entrants can still appear in certain geographies due to:
  • local manufacturing approvals
  • tender-driven substitution after contract expiration
• Branded revenue typically becomes an accounting residual rather than a growth driver.

---

Does Epzicom face Paragraph IV litigation, and how does that affect revenue?

Answer: In the antiretroviral class, litigation historically has been a mechanism to delay some launches in the originator era, but Epzicom’s current commercial state is largely defined by already-available generics rather than ongoing Paragraph IV outcomes.

Commercial impact of Paragraph IV (category-level)

• Even where litigation delays occur, the eventual market outcome is usually price erosion once patents expire.
• Settlement agreements in older antiretroviral products tend to create “launch timing windows,” after which branded sales shift quickly to generics.

---

How do HIV guideline changes influence Epzicom’s long-term demand?

Answer: Guideline evolution tends to reduce new initiation on older backbone combinations when newer once-daily or higher-barrier backbones are preferred.

Net demand effect

• Lower new starts reduce incremental demand.
• Existing patient churn is slower, supporting residual sales in stable cohorts.

---

What are the commercial drivers for Epzicom in emerging markets versus US/EU?

Answer: Epzicom’s comparative performance depends on local procurement rules and generic availability.

Emerging markets

• Often more rapid adoption of generics through procurement programs.
• Tender processes can select lowest acquisition cost NRTI options.

US/EU

• Brand is typically constrained by:
  • generic competition already established
  • formulary management and substitution
  • updated guideline preference for alternative combinations

---

What manufacturing and supply-chain factors affect Epzicom pricing?

Answer: Generic manufacturing capacity, batch availability, and procurement contract timing drive price volatility more than active-ingredient scarcity.

Supply-chain pressure points

• Active ingredient availability can create short-term pricing spikes, but fixed-dose generic markets generally stabilize quickly.
• If a contract winner reduces supply or faces capacity constraints, payers can switch to alternate generic SKUs, keeping prices competitive.

---

How does Epzicom’s financial trajectory typically look versus newer antiretrovirals?

Answer: Epzicom behaves like a mature, price-compressed legacy NRTI backbone. Newer once-daily, fixed-dose, integrase-based regimens capture growth share.

Revenue shape

• Early growth: branded adoption across HIV treatment programs.
• Mid-life: plateau then compression as generics enter.
• Current: mostly residual branded revenue in markets where contract structures or procurement timing maintain a branded share.

Balance-sheet relevance

• Legacy branded HIV products often become modest revenue contributors.
• R&D and marketing resources shift to new launches and lifecycle management in newer classes.

---

Key takeaways

• Epzicom’s market dynamics are now dominated by generic substitution and procurement economics, not exclusivity.
• The HIV treatment landscape shifted toward once-daily, fixed-dose, integrase-based regimens, reducing new-start demand for older NRTI backbone combinations.
• Competitive pressure from generic abacavir/lamivudine and adjacent fixed-dose alternatives keeps pricing low and branded share limited.
• The financial trajectory aligns with mature antiretroviral products: decline in branded revenue, stable or reduced volume through continued patient persistence, and low incremental upside absent new lifecycle differentiation.

---

FAQs

1) Is Epzicom still used for HIV in patients stable on abacavir/lamivudine?

Yes. Clinical continuation in stabilized patients is a common role when the regimen remains effective and tolerable.

2) Are there safer or more guideline-preferred backbones than abacavir/lamivudine today?

Common guideline pathways favor alternative NRTI backbones paired with modern third agents, which can reduce new starts on abacavir/lamivudine.

3) What is the biggest commercial risk to any branded Epzicom-like product?

Further generic pricing compression and tender-driven formulary switching, typically after contract renewals or additional generic entries.

4) How do hospital tender cycles affect Epzicom pricing and volume?

Tender cycles can cause abrupt shifts in purchasing volume when a buyer awards contracts to lower-cost generics.

5) Does litigation usually change the long-run commercial outcome for legacy HIV fixed-dose brands?

Historically in mature segments, litigation can delay specific launches but often does not reverse the long-run shift toward generic availability and price compression once the exclusivity window closes.

---

References (APA)

No sources were provided in the prompt, and no in-line citations were generated.